MedPath

A randomized, double-blind, placebo-controlled intervention study to assess the therapeutic effect of an extensively hydrolyzed infant formula with an added synbiotic mixture in infants with atopic dermatitis.

Phase 3
Completed
Conditions
atopic dermatitis
eczema
10038716
10040785
Registration Number
NL-OMON39465
Lead Sponsor
Danone Research - Centre for Specialised Nutrition
Brief Summary

Trial ended prematurely

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
144
Inclusion Criteria

- Infants/children with atopic dermatitis
- up to and includig 10 months of age
- Expected daily intake of at least 500ml of the study product

Exclusion Criteria

- Intolerance for any other component of the study product(s)
- History of anaphylactic reaction to cow*s milk protein, including severe cardiovascular symptoms (shock), severe laryngeal edema, and bronchus obstruction.
- Use of antihistamines prior to (48 hours) the study.
- Use of oral steroids prior to (4 weeks) the study.
- Use of antibiotics or antimycotic drugs prior to (4 weeks) the study.
- History or presence of cardiovascular, gastrointestinal, hepatic, renal or respiratory chronic disease other than allergy.
- Major congenital abnormalities.
- Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary outcome parameter in this study is the change of SCORAD after 4<br /><br>months of intervention.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcome parameters in this study are:<br /><br>- The severity of exacerbations of atopic dermatitis.<br /><br>- The amount of topical steroids used.<br /><br>- The severity of asthma-like symptoms and asthma medication use.</p><br>
© Copyright 2025. All Rights Reserved by MedPath